參苓白術(shù)散治療腹瀉型腸易激綜合征的系統(tǒng)評價及臨床觀察
發(fā)布時間：2019-04-15 14:08
【摘要】：目的:系統(tǒng)評價參苓白術(shù)散治療腹瀉型腸易激綜合征的有效性安全性及觀察參苓白術(shù)散治療腹瀉型腸易激綜合征臨床療效。方法:1.系統(tǒng)評價部分:運用系統(tǒng)評價方法,檢索參苓白術(shù)散治療腹瀉型腸易激綜合征的隨機(jī)對照試驗,篩選合格研究,評價研究質(zhì)量,應(yīng)用國際循證醫(yī)學(xué)協(xié)作網(wǎng)提供的統(tǒng)計軟件Revman5.3統(tǒng)計數(shù)據(jù),應(yīng)用Jadad評分法進(jìn)行質(zhì)量評價。臨床按試驗措施的不同分亞組對所收集數(shù)據(jù)進(jìn)行異質(zhì)性檢驗和Meta-分析。2.臨床研究部分:選擇觀察對象共60例,隨機(jī)分為試驗組和對照組,試驗組30例,對照組30例。試驗組給予參苓白術(shù)散水煎劑;對照組給予匹維溴銨片合培菲康膠囊,4周為一療程。一療程后觀察臨床療效。結(jié)果:1.系統(tǒng)評價部分:經(jīng)篩選最終納入18項研究,共1446例,根據(jù)試驗措施不同分為兩組,結(jié)果顯示參苓白術(shù)散在治療D-IBS臨床總有效率、臨床癥狀總積分、腹痛、腹瀉方面的療效均優(yōu)于對照組,均有統(tǒng)計學(xué)意義和臨床意義且無嚴(yán)重不良反應(yīng)。上述結(jié)果說明參苓白術(shù)散加減治療D-IBS較為安全可靠,為臨床用藥提供了參考。2.臨床研究部分:臨床綜合療效方面,實驗組總有效率96.7%,對照組總有效率86.7%,試驗組總有效率高于對照組,經(jīng)分析,兩組存在顯著性差異(P0.05),在臨床綜合療效改善方面試驗組優(yōu)于對照組。試驗組與對照組比較,證候總積分比較有顯著差異(P0.05),說明在中醫(yī)證候總積分改善方面,試驗組優(yōu)于對照組。結(jié)論:1.通過系統(tǒng)評價分析參苓白術(shù)散加減能提高D-IBS的臨床療效,但由于本系統(tǒng)評價納入研究質(zhì)量低且樣本量小,藥物安全性不明確,尚需高質(zhì)量隨機(jī)對照試驗進(jìn)一步評價。2.臨床研究表明參苓白術(shù)散治療腹瀉型腸易激綜合征優(yōu)于匹維溴銨片合培菲康膠囊。
[Abstract]:Aim: to evaluate the efficacy and safety of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome and to observe the clinical efficacy of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome. Methods: 1. In the part of systematic evaluation, the randomized controlled trials of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome were searched, qualified studies were screened, and the quality of the study was evaluated. The Revman5.3 statistical data provided by the International Collaborative Network for evidence-based Medicine (EBM) were used to evaluate the quality by using the Jadad scoring method. Clinical heterogeneity test and Meta- analysis of collected data according to different subgroups of trial measures. 2. Clinical study: 60 cases were randomly divided into experimental group and control group, 30 cases in experimental group and 30 cases in control group. The experimental group was given Shenling Baizhu powder decoction, and the control group was given Peiwei ammonium bromide tablet and Peifeikang capsule for 4 weeks as a course of treatment. The clinical curative effect was observed after a course of treatment. Results: 1. In the part of systematic evaluation: 1446 cases were divided into two groups according to different test measures. The results showed that Shenling Baizhu powder was effective in the treatment of D-IBS, the total score of clinical symptoms, abdominal pain, and total score of clinical symptoms, and the results showed that Shenling Baizhu powder was effective in the treatment of D-IBS. The curative effect of diarrhea was better than that of control group, with statistical and clinical significance and no serious adverse reaction. The above results indicate that Shenling Baizhu Powder is safe and reliable in the treatment of D-IBS, which provides a reference for clinical use of drugs. 2. Clinical research part: the clinical comprehensive curative effect aspect, the experimental group total effective rate is 96.7%, the control group total effective rate is 86.7%, the experimental group total effective rate is higher than the control group, through the analysis, the two groups have significant difference (P0.05), The experimental group was superior to the control group in the improvement of clinical comprehensive curative effect. Compared with the control group, there was significant difference between the experimental group and the control group (P0.05), which indicated that the experimental group was better than the control group in the improvement of the total integral of TCM syndrome. Conclusions: 1. Through the systematic evaluation and analysis of Shenling Baizhu Powder can improve the clinical efficacy of D-IBS, but due to the low quality and small sample size of this system evaluation study, drug safety is not clear, it needs to be further evaluated by high-quality randomized controlled trial. 2. Clinical studies show that Shenling Baizhu Powder is superior to Pivoxil tablets in the treatment of diarrhea-type irritable bowel syndrome.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R259
本文編號：2458214
[Abstract]:Aim: to evaluate the efficacy and safety of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome and to observe the clinical efficacy of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome. Methods: 1. In the part of systematic evaluation, the randomized controlled trials of Shenling Baizhu Powder in the treatment of diarrhea irritable bowel syndrome were searched, qualified studies were screened, and the quality of the study was evaluated. The Revman5.3 statistical data provided by the International Collaborative Network for evidence-based Medicine (EBM) were used to evaluate the quality by using the Jadad scoring method. Clinical heterogeneity test and Meta- analysis of collected data according to different subgroups of trial measures. 2. Clinical study: 60 cases were randomly divided into experimental group and control group, 30 cases in experimental group and 30 cases in control group. The experimental group was given Shenling Baizhu powder decoction, and the control group was given Peiwei ammonium bromide tablet and Peifeikang capsule for 4 weeks as a course of treatment. The clinical curative effect was observed after a course of treatment. Results: 1. In the part of systematic evaluation: 1446 cases were divided into two groups according to different test measures. The results showed that Shenling Baizhu powder was effective in the treatment of D-IBS, the total score of clinical symptoms, abdominal pain, and total score of clinical symptoms, and the results showed that Shenling Baizhu powder was effective in the treatment of D-IBS. The curative effect of diarrhea was better than that of control group, with statistical and clinical significance and no serious adverse reaction. The above results indicate that Shenling Baizhu Powder is safe and reliable in the treatment of D-IBS, which provides a reference for clinical use of drugs. 2. Clinical research part: the clinical comprehensive curative effect aspect, the experimental group total effective rate is 96.7%, the control group total effective rate is 86.7%, the experimental group total effective rate is higher than the control group, through the analysis, the two groups have significant difference (P0.05), The experimental group was superior to the control group in the improvement of clinical comprehensive curative effect. Compared with the control group, there was significant difference between the experimental group and the control group (P0.05), which indicated that the experimental group was better than the control group in the improvement of the total integral of TCM syndrome. Conclusions: 1. Through the systematic evaluation and analysis of Shenling Baizhu Powder can improve the clinical efficacy of D-IBS, but due to the low quality and small sample size of this system evaluation study, drug safety is not clear, it needs to be further evaluated by high-quality randomized controlled trial. 2. Clinical studies show that Shenling Baizhu Powder is superior to Pivoxil tablets in the treatment of diarrhea-type irritable bowel syndrome.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R259
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 陳君臻;;經(jīng)方診治腹瀉型腸易激綜合征[J];亞太傳統(tǒng)醫(yī)藥;2015年17期
2 張永順;李雪青;朱葉珊;;靈龜八法貼敷治療腹瀉型腸易激綜合征30例[J];河南中醫(yī);2015年08期
3 夏齊國;馮鑫鑫;黃建華;陳雷;應(yīng)薦;;推拿配合藥餅灸改善脾腎陽虛腹瀉型腸易激綜合征患者腹痛癥狀的臨床觀察[J];浙江中醫(yī)雜志;2015年07期
4 甄杰武;文慧華;;參苓白術(shù)散治療腹瀉型腸易激綜合征的臨床研究[J];中醫(yī)臨床研究;2015年19期
5 袁瑞興;;縮脾法在腹瀉型腸易激綜合征中臨床應(yīng)用體會[J];實用中西醫(yī)結(jié)合臨床;2015年06期
6 朱創(chuàng)鍵;;雙歧三聯(lián)活菌膠囊聯(lián)合參苓白術(shù)散對腹瀉型IBS患者血漿SS和NPY水平影響及療效觀察[J];中國微生態(tài)學(xué)雜志;2015年05期
7 金欣;陳勤;;桔梗的藥理作用研究新進(jìn)展[J];現(xiàn)代中藥研究與實踐;2015年02期
8 王建梅;;針刺為主治療腸易激綜合征43例臨床觀察[J];中國民間療法;2014年12期
9 董桂芬;;參苓白術(shù)散加減治療腸易激綜合癥35例[J];光明中醫(yī);2014年11期
10 武建華;;溫針灸治療腹瀉型腸易激綜合征療效觀察[J];中國中醫(yī)藥信息雜志;2014年11期
，本文編號：2458214
本文鏈接：http://sikaile.net/zhongyixuelunwen/2458214.html
最近更新
教材專著
